Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acid-based antisense: A potential new drug candidate for pancreatic cancer

Keyphrases

• Antisense 100%
• Pancreatic Cancer 100%
• Gene Expression 100%
• KRAS G12C 100%
• Peptide nucleic Acid 100%
• Novel Peptide 100%
• New Drug Candidate 100%
• K-ras 100%
• KRAS mutation 57%
• Mutated KRAS 42%
• Mutated Genes 28%
• G12D 28%
• Intracellular Signaling 14%
• Gene Sequencing 14%
• Protease 14%
• RNA Sequencing (RNA-seq) 14%
• DNA Sequencing 14%
• MRNA-seq 14%
• Therapeutic Approaches 14%
• Quantitative PCR 14%
• Cancer Cells 14%
• Apoptotic Cell Death 14%
• Cellular Models 14%
• Western Blotting 14%
• Antisense Molecules 14%
• AsPC-1 Cells 14%
• Simple Chemical Structure 14%
• Antisense Agents 14%
• Nuclease 14%
• Pancreatic Adenocarcinoma 14%
• Cell Transformation 14%
• GTPase 14%
• Hybridization Specificity 14%
• Antisense Technology 14%
• Biological Stability 14%

Biochemistry, Genetics and Molecular Biology

• Gene Expression 100%
• KRAS 100%
• Peptide Nucleic Acid 100%
• Antisense 100%
• Mutated Genes 25%
• Messenger RNA 25%
• Intracellular Signaling 12%
• Gene Sequence 12%
• DNA Sequence 12%
• GTPase 12%
• RNA Sequence 12%
• Cancer Cell 12%
• Reverse Transcription Polymerase Chain Reaction 12%
• Antisense RNA 12%
• Cell Transformation 12%
• Antisense Technology 12%
• Chemical Structure 12%
• Western Blot 12%
• Protease 12%
• Nuclease 12%
• Programmed Cell Death 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Pancreas Cancer 100%
• Peptide Nucleic Acid 100%
• Messenger RNA 28%
• Malignant Neoplasm 14%
• Pancreas Adenocarcinoma 14%
• Complementary DNA 14%
• Western Blot 14%
• Proteinase 14%
• Nuclease 14%
• Complementary RNA 14%
• Guanosine Triphosphatase 14%
• Antisense Molecule 14%